Monographie - Carmustine

Last update :
19/11/2024

Carmustine

Chemical structure

Tradename

Trade names are indicative and excipients composition can be different depending on the country and manufacturers

Becenun	Brazil
Bicnu	Australia, Canada, Chile, Colombia, France, Great Britain, Greece, Hungary, Iran, Ireland, Mexico, Morocco, New Zealand, Peru, Romania, Spain, Switzerland, Tunisia, United States of America
Bodacler	Argentina
Carmubris	Austria, Germany, Iran
Carmustina Grey	Peru
Carmustina Perulab	Peru
Carmustine Baxter	New Zealand
Carmustine Obvius	Austria, Belgium, Bulgaria, Croatia, Czech Republic, Denmark, Finland, France, Germany, Great Britain, Hungary, Iceland, Ireland, Luxembourg, Netherlands, Norway, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden
Nitrourean	Spain
Nitrumon	Belgium, Iran, Luxembourg

References : Carmustine

	Type	Publication
3	Journal	Trissel LA, Martinez JF. Compatibility of amifostine with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 2208-2212.
81	Journal	Trissel LA, Martinez JF. Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 672-678.
84	Journal	Trissel LA, Martinez JF. Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 495-499.
99	Journal	Trissel LA, Martinez JF. Compatibility of aztreonam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
146	Journal	Hadji-Minaglou-Gonzalvez MF, Gayte-Sorbier A, Airauto CB, Verdier M. Effects of temperature, solution composition, and type of container on the stability and absorption of carmustine. Clin Ther 1992 ; 14: 821-824.
169	Journal	Trissel LA, Martinez JF. Physical compatibility of melphalan with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1993 ; 50: 2359-2363.
182	Journal	Trissel LA, Gilbert DL, Martinez JF. Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 56-60.
244	Journal	Trissel LA, Martinez JF. Compatibility of filgrastim with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1907-1913.
249	Journal	Trissel LA, Martinez JF. Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
307	Journal	Trissel LA, Martinez JF. Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1792-1799.
334	Journal	Trissel LA, Tramonte SM, Grilley BJ. Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 988-992.
335	Journal	Trissel LA, Bready BB, Kwan JW, Santiago NM. Visual compatibility of sargramostim with selected antineoplasic agents, anti-infectives, or other drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 402-406.
492	Journal	Trissel LA, Parks NPT, Santiago NM. Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 2186-2189.
715	Journal	Colvin M, Hartner J, Summerfield M. Stability of carmustine in the presence of sodium bicarbonate. Am J Hosp Pharm 1980 ; 37: 677-678.
837	Journal	Fredriksson K, Lundgren P, Landersjo L. Stability of carmustine - kinetics and compatibility during administration. Acta Pharm Suec 1986 ; 23: 115-124.
905	Journal	Trissel LA, Martinez JF. Screening teniposide for Y-site physical incompatibilities. Hosp Pharm 1994 ; 29: 1010-1017.
1410	Journal	Trissel LA, Martinez JF, Simmons M. Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 141-145.
1423	Journal	Trissel LA, Martinez JF, Gilbert DL. Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 514-518.
1501	Journal	Beitz C, Bertsch T, Hannak D, Schrammel W, Einberger C, Wehling M. Compatibility of plastics with cytotoxic drug solutions - comparison of polyethylene with other container materials. Int J Pharm 1999 ; 185: 113-121.
1520	Manufacturer	Etude de stabilité des médicaments en Ecoflac® B Braun 2001
1622	Journal	Favier M, De Casanove F, Coste A, Cherti N, Bressolle F. Stability of carmustine in polyvinyl chloride bags and polyethylene-lined trilayer plastic containers. Am J Health-Syst Pharm 2001 ; 58: 238-241.
2146	Journal	Trissel LA, Xu QA, Baker M. Drug compatibility with new polyolefin infusion solution containers. Am J Health-Syst Pharm 2006 ; 63: 2379-2382.
3314	Manufacturer	Carmustine (Bicnu®) – Résumé des caractéristiques du produits Bristol Myers Squibb 2011
4762	Journal	Knoll L, Kraemer I, Thiesen J. Physicochemical stability of carmustine-containing medicinal products after reconstitution and after dilution to ready-to-administer infusion solutions stored refrigerated or at room temperature EJHP 2023 ; 30, 1: 11-16.

Mentions Légales